DSIP (Delta Sleep-Inducing Peptide)
An Antibody Reports What It Binds, Not What Is There
Radioimmunoassay quantifies how much material in a sample competes with a labelled standard for antibody binding. It measures immunoreactivity, which is what an antibody recognises — not necessarily the molecule the antibody was raised against.
Key facts
- Measures
- Competition for antibody binding
- Reports
- Immunoreactivity
- Does not establish
- Molecular identity
- Cross-reactivity
- Any molecule sharing the epitope
- Standard hedge
- '-like material', 'immunoreactive X'
- Confirmation requires
- Chromatography, mass spectrometry
How the method works
A known quantity of labelled peptide and an antibody are mixed with the sample. Anything in the sample that binds the antibody displaces some labelled peptide, and the amount displaced is converted into a concentration. It is sensitive, it scales well, and it was the workhorse of peptide endocrinology for decades.
What the antibody actually recognises
An epitope — a small region of the molecule, often only a handful of residues. Anything presenting that region will bind, whether it is the intended peptide, a fragment containing it, a larger precursor, or an unrelated molecule that happens to display a similar surface. The assay cannot distinguish between them, because binding is all it measures.
Research material referenced
DSIP 5mg — third-party HPLC tested
Why the hedged phrasing exists
Careful authors write DSIP-like material or immunoreactive DSIP rather than DSIP. That is not stylistic caution — it is a precise statement that the assay detected something the antibody bound, and that identity was not established. Where a paper uses the hedge and a summary of it drops the hedge, the claim has been strengthened without any new evidence.
How the ambiguity gets resolved
By separating the sample before measuring it. Chromatography sorts material by size, so running immunoreactive fractions on a column shows whether the signal sits where the peptide should. If it appears at a much larger size, the antibody is binding something else. Mass spectrometry settles identity outright.
Why this matters for the DSIP literature specifically
Most of the tissue distribution work behind this compound's reputation was generated by radioimmunoassay in the 1980s. Whether those measurements identified the peptide or a family of larger molecules sharing an epitope is a question the method cannot answer on its own — and one the original authors examined directly.
What this is not
A criticism of the technique or of the researchers who used it. Radioimmunoassay was and is a legitimate and sensitive method, and the people who used it generally stated its limits accurately. The problem arises downstream, where careful phrasing is discarded by people summarising the work.
Extended research context
The DSIP (Delta Sleep-Inducing Peptide) deep dive
Deep dive: a name that was a hypothesis, not a finding
In 1977 the Schoenenberger-Monnier group in Basel electrically stimulated the thalamus of a sleeping rabbit, collected blood draining from its brain, isolated a peptide fraction, and reported that administering it into the ventricles of awake rabbits produced delta-wave EEG activity. They named it delta sleep-inducing peptide. By the standards of the time this was careful, imaginative work, and they followed it properly - the 1978 Pflugers Archiv paper reported sequence, synthesis and activity of the synthetic nonapeptide rather than stopping at a suggestive fraction. The problem is not the original research. It is that a name recording a hypothesis has been read ever since as a summary of established pharmacology, and almost nobody checks whether it was earned.
Deep dive: the three things that are missing
A proposed endogenous peptide becomes accepted biology by a recognisable route. The gene is located. The precursor protein is characterised. A receptor is identified, giving a mechanism and a testable target. DSIP has completed none of these in nearly fifty years. The receptor gap is the most disabling - without one there is no mechanism to test, no dose-response to build, no antagonist to design, and no way to establish that an observed effect runs through the proposed pathway at all. The gene gap is the hardest to explain away: modern genomics located MOTS-c inside a short open reading frame nested within the mitochondrial 12S rRNA gene, sequence already annotated as something else. That a peptide described in 1977 still has no identified gene in any genome is a substantive observation, not an accident of effort.
Deep dive: why 519 papers is not 519 confirmations
DSIP has roughly 519 indexed PubMed records - more than Selank's 135 or Semax's 231. Publication volume tracks how interesting a question is, not how well it has been answered. A tractable question generates a burst of work and then stops; a question that resists resolution generates papers indefinitely, each a further attempt rather than a further confirmation. Kovalzon's 2006 review in the Journal of Neurochemistry states the field's own assessment in its title: a still unresolved riddle. Reading any individual DSIP paper without that context invites mistaking activity for consensus.
Research applications
- ▸Historical study of humoral sleep-factor hypotheses
- ▸Electroencephalography and delta-wave research methodology
- ▸Structure-activity work on flexible, acidic short peptides
- ▸Comparative work on peptides lacking identified receptors
- ▸Analytical method development for tryptophan-containing peptides
Handling checklist
- ✓Store lyophilised material cold, dry and protected from light
- ✓No reducing agent needed — the sequence contains no cysteine
- ✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
- ✓Protect from prolonged light — the single tryptophan is mildly photosensitive
- ✓Expect pH-dependent solubility; the peptide is strongly acidic with no basic residue
- ✓Aliquot to avoid repeated freeze-thaw cycles
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Treating the name as evidence of the effect
Fix: The name records a 1977 hypothesis from a single rabbit EEG study. It is not a summary of established pharmacology.
✗ Citing the 1977 paper as proof DSIP induces sleep
Fix: It reports delta-wave EEG activity in rabbits after intraventricular administration — a narrower claim than inducing sleep, in one species, by a route that bypasses every normal barrier.
✗ Assuming DSIP is an established endogenous human peptide
Fix: No gene has been identified in any species, no precursor characterised and no receptor found.
✗ Reading 519 papers as 519 confirmations
Fix: Volume reflects an unresolved question attracting sustained attempts, not accumulated confirmation.
✗ Making any sleep claim about supplied material
Fix: The evidence does not support it and a therapeutic claim about research material is what MHRA enforcement targets.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- What is DSIP?
- Does DSIP actually induce sleep?
- How was DSIP discovered?
- Does DSIP have a receptor?
- What are delta waves?
- Is DSIP approved anywhere?
Frequently asked questions
- What does a radioimmunoassay measure?
- How much material competes with a labelled standard for antibody binding — immunoreactivity, not molecular identity.
- Why do papers say 'DSIP-like material'?
- It is a precise hedge meaning the antibody bound something, and identity was not established.
- How is identity confirmed?
- Chromatography to check the signal appears at the right size, and mass spectrometry to settle it outright.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedGraf MV, Kastin AJ, Delta sleep-inducing peptide (DSIP)-like material exists in peripheral organs of rats in large dissociable forms — Proc Soc Exp Biol Med 1984 (PMID 6548030)pubmed.ncbi.nlm.nih.gov
- PubMedBjartell A et al., Immunoreactive delta sleep-inducing peptide in the rat hypothalamus, pituitary and adrenal gland — Horm Res 1991 (PMID 1814802)pubmed.ncbi.nlm.nih.gov
- PubMedGraf MV, Delta-sleep-inducing peptide (DSIP): an update — Peptides 1986 (PMID 3550726)pubmed.ncbi.nlm.nih.gov
- PubMedSchoenenberger GA et al., Characterization of a delta-EEG (sleep)-inducing peptide — PNAS 1977 (PMID 265572)pubmed.ncbi.nlm.nih.gov
- PubMedSchoenenberger GA et al., DSIP XI: amino-acid analysis, sequence, synthesis and activity — Pflugers Arch 1978 (PMID 568769)pubmed.ncbi.nlm.nih.gov
- PubMedKovalzon VM, Delta sleep-inducing peptide (DSIP): a still unresolved riddle — J Neurochem 2006 (PMID 16539679)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Delta sleep-inducing peptide (CID 68816)pubchem.ncbi.nlm.nih.gov
- PubMedPubMed — DSIP literaturepubmed.ncbi.nlm.nih.gov
- RefMHRA — Medicines and Healthcare products Regulatory Agencygov.uk
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More DSIP (Delta Sleep-Inducing Peptide) articles
- What the Antibody Found in Peripheral TissueGraf and Kastin measured DSIP-like material across 12 rat tissues — highest in stomach — then showed chromatography put most of it at a larger size.
- What Adrenalectomy ChangedBjartell 1991 measured immunoreactive DSIP in rat hypothalamus, pituitary and adrenal gland, and examined what removing the adrenals did to it.
- A Question Mark in the Title Is Doing Real WorkGimble 2009 proposed links between DSIP, glucocorticoid-induced leucine zipper, circadian mechanisms and obesity — and framed it as a question.
- What the Field Said After Its First DecadeGraf published a DSIP update in Peptides in 1986. Reading a review from the middle of a literature shows what was expected but never arrived.
- The Barrier Any Central Claim Has to CrossA compound said to act on sleep must reach the brain. The blood-brain barrier excludes most peptides, and getting across is an engineering problem.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- Retatrutide ResearchHow One Peptide Engages Three Receptors
- GHK-Cu (Copper Peptide)GHK-Cu in the Published Literature
- TB-500 (Thymosin β4 fragment)BPC-157 and TB-500 Together: What the Evidence Says
- BPC-157 (Pentadecapeptide)BPC-157 Studied Effects, Sorted by Evidence
- CJC-1295 & IpamorelinStorage and Reconstitution for Both Compounds
- Peptide ReferenceHPLC and Mass Spectrometry: What Each Answers
- Bacteriostatic WaterHow Benzyl Alcohol Works as a Preservative
- Research & Regulatory NewsWhat the Systematic Reviews Say About Children and Adolescents
- GLP-1 & Incretin ScienceThe Gallbladder Case Is Unusually Complete
- MOTS-c (Mitochondrial Peptide)The Structural Reasons the Evidence Is Thin
- Semax (ACTH Fragment Peptide)What a Fragment Keeps Decides What It Does
- Selank (Tuftsin Analogue)What an Aversive-Signs Model Measures
- KLOW (Blend)KLOW Regulatory Status
- GLOW (Blend)GLOW Regulatory Status
- MT-2 (Melanotan II)The Receptor a Non-Selective Agonist Also Reaches
- IGF-1 LR3Eighty-Three Residues, and What That Changes
- GlutathioneKidney and Intestine, and Why Position Matters
- NAD+Separate Pools in Separate Compartments
- KPVKPV Regulatory Status